Heme oxygenase-1 (HO-1) is an anti-inflammatory enzyme that maintains homeostasis during cellular stress. Given previous findings that shorter length variants of a HO-1 promoter region GT n microsatellite polymorphism are associated with increased HO-1 expression in cell lines, we hypothesized that shorter variants would also be associated with increased levels of HO-1 expression, less inflammation and lower levels of inflammation-associated viral replication in human immunodeficiency virus (HIV)-infected subjects. Healthy donors (n ¼ 20) with shorter GT n repeats had higher HO-1 mRNA transcript in peripheral blood mononuclear cells stimulated with lipopolysaccharide (r ¼ À0.38, P ¼ 0.05). The presence of fewer GT n repeats in subjects with untreated HIV disease was associated with higher HO-1 mRNA levels in peripheral blood (r ¼ À0.41, P ¼ 0.02); similar observations were made in CD14 þ monocytes from antiretroviral-treated subjects (r ¼ À0.36, P ¼ 0.04). In African-Americans, but not Caucasians, greater GT n repeats were correlated with higher soluble CD14 levels during highly active antiretroviral therapy (r ¼ 0.38, P ¼ 0.007) as well as higher mean viral load off-therapy (r ¼ 0.24, P ¼ 0.04). These data demonstrate that the HO-1 GT n microsatellite polymorphism is associated with higher levels of HO-1 expression and that this pathway may have important effects on the association between inflammation and HIV replication.
INTRODUCTION
Although host immune activation is critical for the eradication of infectious agents, the inflammatory response can also enhance pathogenesis. An example of this delicate balance is revealed by human immunodeficiency virus (HIV) disease: progressive and pathogenic infection is associated with chronic immune activation, including heightened destruction and diminished production of T lymphocytes, 1 an increased frequency of T cells with an activated phenotype, 2 increased T-cell induction of the pro-inflammatory transcription factors, NFkB and NF-AT, 3 and increased serum levels of pro-inflammatory cytokines (for example, TNFa, IL-1 and IL-6). 4, 5 The impact of chronic inflammation on HIV (and simian immunodeficiency virus) disease progression has been well studied in both humans and non-human primates. Experiments in nonhuman primate models of acute simian immunodeficiency virus infection have demonstrated that increased bystander immune activation heightens viral cellular transmission by increasing the T-cell target to T-cell effector ratio. 6 T lymphocyte activation as measured by cell surface markers has also been associated with viral load 'set-point' in untreated HIV disease, 7 and is associated with disease progression in both untreated and treated HIV infection. 8, 9 Multiple mechanisms likely contribute to HIV-associated inflammation, including the direct effects of the virus. Recent studies have shown that circulating lipopolysaccharide (LPS) resulting from microbial translocation from the gut is a cause of the systemic immune activation in chronic HIV infection, 10 and is present even in highly active antiretroviral therapy (HAART)-suppressed subjects with undetectable viremia. 11 An extension of this finding was the discovery that soluble CD14 (sCD14), the portion of the LPSreceptor that gets cleaved upon binding to its ligand, is elevated in HIV disease and strongly associated with enhanced mortality in chronically HIV-infected subjects, 12 and is a major force driving chronic inflammation in HAART-treated patients. 13 Given the impact of immune activation/inflammation on the pace of HIV disease progression, we hypothesized that the host factors controlling inflammation might be protective. In this study, we focused on heme oxygenase-1 (HO-1), the rate-limiting enzyme that initiates heme degradation and maintains cellular homeostasis during stress through its depletion of pro-oxidant heme, through the generation of cytoprotective carbon monoxide and biliverdin, and through induction of ferritin by Fe 2 þ release. HO-1 is induced by a myriad of stress signals including oxidative stress, ultraviolet radiation and the pro-inflammatory cytokines IL-1, IL-6 and TNFa. 14 Furthermore, we have recently demonstrated that the HO-1 inhibitor, tin mesoporphyrin IX (SnMP), induces activation, proliferation and maturation of naïve human T cells via interactions with CD14 þ monocytes. 15 Given the important role that HO-1 has as an anti-inflammatory mediator, numerous studies have linked proximal promoter HO-1 polymorphisms to disease states that are driven by inflammation (for example, graft vs host disease, ischemic stroke, coronary artery disease and so on) (reviewed in Exner et al.) . The GT n microsatellite polymorphism is the best-characterized HO-1 genetic locus to date. Previous studies using promoter-luciferase assays in cell lines have shown an association between the GT n microsatellites with a small number of repeats and enhanced transcription of the HO-1 gene. 17 --20 Likewise, a recent study using primary endothelial cells isolated from newborns showed that HO-1 induction was more robust in the context of fewer (GT no23 ) than greater (GT X29 ) repeats. 21 Although many candidate gene studies have detected associations between the short HO-1 GT n microsatellite variant and the control of inflammatory disease states, no study has examined its functional role in regulating gene expression in primary immune cells that directly influence pathogenic outcomes in the HIV-infected subjects.
Here, we have studied the influence of the promoter GT n microsatellite repeat number on HO-1 transcript expression in peripheral blood mononuclear cells (PBMCs) of healthy adults after in-vitro stimulation and in PBMCs isolated from HIV-infected subjects on and off antiretroviral therapy. Next, we conducted a candidate genotyping study for two biomarkers of HIV disease progression: mean viral load and sCD14. Lastly, we determined the association between HO-1 expression and CD14 expression on primary blood CD14 þ monocytes from healthy donors stimulated in vitro with LPS. In aggregate, our results suggest that the HO-1 GT n microsatellite polymorphism is a functional determinant of HO-1 expression in primary immune cells and is associated with important biomarkers of HIV disease outcome.
RESULTS

HO-1 promoter description across HIV-infected subjects of different ethnicities
The HO-1 promoter region analyzed extends from the nucleotide position 1876 bp upstream and þ 75 bp downstream of the transcription start site at position þ 1 (Figure 1a ). This promoter region contains the GT n dinucleotide repeat and two common SNPs ( --413AT/rs2071746 and --1195AG/rs3761439) that have been analyzed in previous studies of the HO-1 gene. 19, 22 Two common insertion/deletion variants (dbSNP ID rs72441698 and rs58433947) with GT 7 repeats may explain the large frequency of GT 23 and GT 30 variants seen across all the populations of HIV-infected subjects (n ¼ 717, median age ± interquartile range ¼ 46.2 ± 10.2, 85.5% male, 28.6% African-American, 55.2% Caucasian) ( Supplementary Figure 1) . The GT n repeats in the African-Americans follow a tri-modal distribution in contrast to the bi-modal distribution seen in the Caucasians (Box III in Figure 1b ). The addition of this GT 7 insertion results in greater repeat numbers in African-Americans (mean 31.5±0.27, n ¼ 205) than in the Caucasians (mean 28.1±0.14, n ¼ 396) (Po0.001) ( Figure 1b ) and in other ethnic groups ( Supplementary Figure 1a ). Allele frequencies for these SNPs were also calculated across these ethnic groups ( Supplementary Figure 1b) .
Prior studies of the HO-1 promoter region examined the association between the --413AT/rs2071746 and the --1195AG/ rs3761439 SNPs with coronary artery disease outcomes and cardiac function during exercise. 19, 22 These SNPs were not in significant linkage disequilibrium with the most common GT23 and GT30 repeats in both the African-American and the Caucasian populations ( Figure 1c ), with r2 values below 0.4. These results suggest limited linkage disequilibrium present at this locus.
HO-1 additive GT n repeats negatively correlate with gene expression in PBMCs and CD14 þ monocytes from healthy donors To extend these studies to primary cells that might be involved in the immune response to HIV, fresh PBMCs (n ¼ 20) or enriched CD14 þ monocytes from healthy donors (n ¼ 6) (subsets of donors from those listed in Table 1 ) were analyzed for HO-1 relative transcript expression after stimulation with the HO-1 chemical inducers cobalt protoporphyrin IX (CoPP), hydrogen peroxide (H 2 O 2 ) and LPS. Compared with the phosphate-buffered saline control, stimulation with CoPP led to a 46-fold increase in relative transcript abundance of HO-1 (Po0.0001, paired t-test), whereas H 2 O 2 stimulation led to a 1.3-fold increase (P ¼ 0.005) and LPS to a 1.3-fold decrease (P ¼ 0.007) ( Figure 2a ). As prior studies have reported an important role of HO-1 in the function of CD14 þ monocytes, 19, 22 enriched CD14 þ monocytes were analyzed after in-vitro stimulation with CoPP, H 2 O 2 or LPS, which led to a 30-fold increase (Po0.0001), a 1.2-fold increase (P ¼ 0.02) and a 1.4-fold decrease (P ¼ 0.02), respectively (paired t-test, Figure 2b ).
Using an HO-1 promoter-reporter gene assay in HEK293T cells, the additive sum of an individual's GT n repeat number (GT n locus 1 þ GT n locus 2 ) was found to be an informative variable for subsequent functional analyses of this polymorphism (that is, the greater the repeat number the lower the level of HO-1 expression) ( Supplementary Figure 2 ). Healthy donors were genotyped for the HO-1 GT n polymorphism, and transcript levels in PBMCs were measured. Multiple regression analysis (controlling for self-identified ethnicity) of normalized HO-1 transcript level and additive GT n repeats showed statistically significant negative correlations in PBMCs from healthy donors stimulated with LPS (r ¼ À0.38, b ¼ À0.024, P ¼ 0.05) ( Figure 2c ). The same analyses in PBMCs stimulated with CoPP (r ¼ À0.30, b ¼ À0.98, P ¼ 0.06) and H 2 O 2 (r ¼ À0.36, b ¼ À0.076, P ¼ 0.08) showed trends toward negative correlations ( Figure 2c ). Consistent with previous findings, the HO-1 transcript levels in unstimulated PBMCs did not show a correlation with an individual's additive GT n repeat number 20 (Supplementary Figure 3 ). These results are consistent with our gene expression results in the HEK293T cell lines as well as prior reports showing that greater GT n repeats lead to decreased gene expression. 17 --19 Finally, given prior evidence that the À413AT/rs2071746 may be associated with HO-1 expression in cell lines, 19 we tested whether this SNP was associated with HO-1 induction in primary PBMCs exposed to CoPP, LPS or H 2 O 2 (Supplementary Figures 4a--c, respectively). Analysis of variance analysis showed no significant association between the HO-1 gene expression with this SNP or another common SNP (--1195AG/rs3761439). In summary, these results show that the GT n microsatellite polymorphism is associated with the regulation of HO-1 gene transcription in primary immune cells.
HO-1 additive GT n repeats negatively correlate with gene expression in PBMCs and CD14 þ monocytes from HIV-infected subjects Prior studies have shown that HIV infection leads to upregulation of HO-1 mRNA levels in the peripheral blood cells. 23 To determine whether HIV-infected subjects with a greater number of additive GT n repeats displayed lower HO-1 expression, we harvested thawed PBMCs and measured relative HO-1 transcript abundance. Multiple regression analysis with ethnicity as a covariate was performed to determine the relationship between the number of additive GT n repeats and HO-1 relative transcript levels in 'viral non-controllers' (prototypic HIV-infected adults with plasma HIV RNA levels above 10 000 copies RNA per ml, n ¼ 34) (Table 2a) and 'viral controllers' (HIV-infected adults able to fully or partially control HIV replication with plasma HIV RNA level below 1000 copies RNA per ml in the absence of therapy, n ¼ 30) (Table 2a) . T-lymphocyte activation for each patient was measured with the co-staining of HLA-DR (human leukocyte antigen-DR) and CD38 on CD4 þ and CD8 þ T cells. Among the non-controllers, there was a significant correlation between the additive GT n repeats and the HO-1 relative transcript level (Figure 3a) (r ¼ À0.41, b ¼ À3.08, P ¼ 0.02). There was no association between these factors in the controllers (r ¼ 0.03, b ¼ À0. 36 ,
Further phenotyping analyses in PBMCs from HIV-infected subjects on HAART showed that HO-1 was expressed to the highest extent in CD14 þ monocytes. Among individuals with a favorable response to HAART (as defined by having a plasma viral loads with o75 copies RNA per ml) (Table 2b) , there was a negative correlation in CD14 þ monocytes (r ¼ À0. 36 , b ¼ À30.45, P ¼ 0.04) ( Figure 3b ). These results suggest that the GT n microsatellite polymorphism is an important correlate of HO-1 expression within peripheral immune cells during the course of HIV disease, especially in those subjects with progressive disease and high viremia.
HO-1 additive GT n repeats are correlated with levels of sCD14 and viremia in African-American HIV-infected subjects Given recent studies linking high levels of sCD14 with enhanced mortality in chronically HIV-infected subjects on HAART 12 and the functional role that HO-1 has in CD14 þ monocyte biology, Figure 1 . HO-1 promoter description and variation across HIV-infected subjects of different ethnicities. (a) HO-1 promoter region (from À1876 to þ 75) encompassing subcloning region, GT n repeat, sequencing primers and transcription start site (TSS) at position þ 1. The GT n dinucleotide repeat is shown in the boxed area (extending from 260 bp to 200 bp upstream of the TSS) and two common SNPs ( --413AT/ rs2071746 and --1195AG/ rs3761439) are shown. Two common insertion deletion variations (dbSNP ID rs72441698 and rs58433947) with GT 7 repeats are shown in bold font within the GT n repeat. Microsatellite sequencing primers for capillary electrophoresis are denoted by 'MS-Primer1' and 'MS-Primer2.' Subcloning primers for the promoter-reporter gene expression assay are denoted by 'S-primer1' and 'S-primer2.' (b) GT n allele frequencies within the HIV-infected patients reported as (mean±s.e.m.): the African-Americans (31.5±0.27, n ¼ 205) and the Caucasians (28.1 ± 0.13, n ¼ 396) (difference in mean length between ethnic groups, Po0.0001, Student's unpaired t-test). Boxes I, II and III represent the distribution of the additive GT n repeats with peaks at GT 23 , GT 30 and GT 37 . (c) The GT n microsatellite repeats that are most represented in all the populations (n ¼ 23 and 30) are not in linkage disequilibrium (LD) with --413AT/rs2071746 and --1195AG/rs3761439 in either Caucasians (n ¼ 396) or African-Americans (n ¼ 205). The top two heat maps represent the pair-wise LD results for African-American patients with GT23 (left) and GT30 (right), with the values in the legend corresponding to the r2 values for each pair-wise comparison between the SNPs --413AT/ rs2071746, --1195AG/rs3761439, and the GT n microsatellite repeat. The bottom two heat maps represent the same for the Caucasian patients.
we measured levels of plasma sCD14 levels in a larger cohort of the African-American and Caucasian HIV-infected, HAART-suppressed subjects. Clinical and laboratory data describing these subjects are provided in Table 3a .
Greater HO-1 additive GT n repeats correlated with higher levels of sCD14 in African-American HAART subjects (n ¼ 50, r ¼ 0.38, P ¼ 0.007) (Table 3a ) ( Figure 4a ). Furthermore, each unit increase in additive GT n repeats correlated with a sCD14 level increase of 2.3 ± 0.8 Â 10 4 pg per ml (regression coefficient b ¼ 2.3). Greater additive GT n repeats also correlated with higher mean plasma HIV RNA levels in the African-American subjects during the chronic phase of infection (n ¼ 74, r ¼ 0.24, P ¼ 0.04) ( Figure 4b ). Further- In summary, these data suggest that the genetically determined level of HO-1 expression in CD14 þ monocytes may have a role in HIV disease outcome in the African-Americans.
Higher levels of HO-1 expression in primary human CD14 hi monocytes correlate with decreased loss of cell surface CD14 after LPS stimulation CD14 is expressed on the cell surface of monocytes and is the receptor for LPS, a cell wall component of Gram-negative bacteria. Upon binding to LPS, a cleaved form of CD14 is shed into the circulation. 24, 25 Given the finding that greater numbers of HO-1 additive GT n repeats are positively correlated with higher levels of sCD14 ( Figure 4a ), we tested the possibility that HO-1 expression in CD14 þ monocytes predicts their ability to retain CD14 cell surface expression upon LPS stimulation. HO-1 protein levels were quantified in PBMCs from 22 healthy donors (Table 1) by multiparameter flow cytometry analysis ( Figure 5a ). As previously demonstrated, 15, 26 HO-1 was most highly expressed at baseline in PBMCs within the CD14 þ blood monocyte population. Upon exposure to CoPP, HO-1 was upregulated to a greater extent within monocytes that are CD14 hi than in 'non-classical' CD14 dim CD16 þ monocytes (55 226 vs 13 448 in geometric mean fluorescence intensity (gMFI); Po1 Â 10 À8 ). By contrast, CD3 þ T cells displayed very low HO-1 expression, even after induction with 25 mM CoPP (Figure 5a ).
We measured HO-1 expression after LPS stimulation and saw a significant decrease in expression of HO-1 gMFI within CD14 hi monocytes (paired t-test, P ¼ 0.04) ( Figure 5b ). As HO-1 is generally considered to be anti-inflammatory, we hypothesized that induction of HO-1 in CD14 hi monocytes after LPS stimulation might positively correlate with the ability of these cells to retain cell surface CD14. To test this hypothesis, the relationship between the change in staining intensities for HO-1 and for (Figure 5c ). Multiple regression analysis (covariates included ethnicity, age and gender) showed an association between the expression of HO-1 and retention of cell surface CD14 in LPS-stimulated CD14 hi monocytes.
Notably, CD14 hi monocytes from individuals with very high GT repeat numbers (460) generally had less induction of HO-1 and greater loss of CD14 when stimulated with LPS (boxed data points, Figure 5c ). These results suggest that the ability to induce HO-1 in CD14 hi monocytes upon exposure to LPS is protective against the loss of CD14 from the cell-surface, which itself is a favorable predictor of outcome in HIV disease.
DISCUSSION
As high levels of immune activation and inflammation predict a more rapid pace of HIV disease progression, 15, 26 host immunoregulatory factors that blunt immune activation and inflammation may contribute to delayed disease progression. Amongst such factors, HO-1 is an important anti-inflammatory enzyme that has been implicated in multiple disorders in the past. In these studies, we have performed an assessment of HO-1 promoter polymorphism genetics, HO-1 expression and two biomarkers associated with HIV disease outcome in a large cohort of well-characterized HIV-infected and -uninfected adults. Our data show that HO-1 GT n microsatellite genotypes predict HO-1 expression in primary cells, and that there is a consistent association between the HO-1 promoter genotype and HO-1 expression. We also show that greater additive GT n repeats correlate with higher viral loads and higher levels of the inflammatory sCD14 biomarker in the HIVinfected African-Americans. Finally, we show that higher levels of HO-1 induction in monocytes correlate with the retention of CD14 on the cell surface after LPS stimulation. In light of these data, we speculate that induction of the anti-inflammatory enzyme HO-1 may have a role in limiting the injurious effects of immune activation in chronic HIV disease, for example, which was caused upon microbial translocation and circulation of LPS. 10, 12 This is in line with the evidence that HO-1 induces tolerogenic properties in monocyte-derived antigen-presenting cells. 15, 26 By influencing monocyte maturation and activation, HO-1 may accordingly represent an anti-inflammatory control mechanism for monocyte-mediated inflammation induced by LPS.
It has long been recognized that individuals with HIV have a higher proportion of circulating CD14 dim CD16 þ inflammatory monocytes than do uninfected controls. 27 --29 Reciprocally, we have observed that the initiation of suppressive HAART therapy in chronically HIV-infected subjects is associated with a decrease in the percentage of circulating CD14 dim CD16 þ inflammatory monocytes and an increase in the percentage of CD14 hi 'conventional' monocytes (Supplementary Figure 6) . Shedding of CD14 from the surface of non-inflammatory CD14 hi monocytes upon exposure to an activating stimulus (for example, LPS) may represent an important part of their transition into pro-inflammatory CD14 dim CD16 þ monocytes, and further studies exploring this possibility are underway.
We also demonstrate that higher copy numbers within the HO-1 GT n repeat promoter polymorphism correlate with higher mean viral load during chronic HIV infection in African-American subjects, suggesting that HO-1 activity can modulate viral load. For this analysis, we focused on individuals with high mean viral loads due to the fact that HO-1 expression is not induced to as high an extent in individuals that are able to control the viral loads (Figures 3a and b) . HO-1 induction may limit bystander immune activation during the acute stage of HIV infection, and thereby reduce the harmful T-cell target to T-cell effector ratio that leads to heightened viral transmission leading into the chronic stage of the infection. 6 Our data show that having fewer GT n repeats within the microsatellite polymorphism of the HO-1 promoter region is associated with higher levels of the HO-1 gene expression in primary immune cells. The alternating purine --pyrimidine repeats within the GT n microsatellite form a left-handed helical Z-DNA conformation and may affect gene transcription through the inhibition of RNA polymerase-mediated transcription. 30 The HO-1 GT n microsatellite locus is unique in being able to influence gene transcription under multiple cellular stress conditions. Our study shows that additive GT n repeats influence HO-1 expression upon CoPP, H 2 O 2 and LPS stimulation, confirming and extending the findings of a recent study analyzing this polymorphism in primary human newborn endothelial cells. 21 The central mediator implicated in this pathway is the Nrf2 transcription factor during HO-1 induction with CoPP and H 2 O 2 , 31,32 and HO-1 downregulation with LPS stimulation. 33 In this study, we report an association between greater additive GT n repeats and plasma sCD14 in HAART-suppressed subjects and mean viral load in chronically HIV-infected, untreated African-American subjects. Interestingly, this association was not observed in the Caucasians. Though individuals of African ancestry have a greater average number of HO-1 GT n repeats within this microsatellite polymorphism than do other ethnic groups ( Supplementary Figure 1) , it does appear that the positive correlation between sCD14 remains consistent even in the range of 40 --70 repeats, which overlaps with the number of repeats seen in the Caucasians. We cannot rule out that there may be epistatic factors, whether environmental or genetic, that differentially influence the HO-1 gene function in the African-Americans vs the Caucasians. For example, ethnicity-specific differences in the interaction of Nrf2 or Bach1 with the promoter region containing the GT n satellite polymorphism may also influence the HO-1 gene expression. Also, we cannot rule out the possibility that interactions with Toll-like receptors, such as TLR4, may influence the extent of CD14 expression on monocytes upon LPS stimulation (Figure 5c ). To our knowledge, this type of regulation has not been explored in the past, 24, 25 but future studies along these lines may reveal new insights about monocyte biology. To better understand the basis of the associations observed in the African-American subjects, it will be necessary to carry out larger cross-population comparisons of the HO-1 genetic locus as well as the upstream mediators influencing its expression.
The prevalence of higher GT n repeat numbers in individuals with African ancestry may reflect an interplay between the HO-1 activity and the various hemolytic conditions that are prevalent in this population (for example, about 75% of the global incidence of hemoglobinopathy is in subSaharan Africa). 34 Indeed, there is an evidence showing positive selection for the genomic region specific to the African ancestral populations, with this group showing a positive Cross Population Expression Haplotype Homozygosity coefficient of 1.8 in contrast to the other populations showing negative Cross Population Expression Haplotype Homozygosity coefficients (Human Genome Diversity Project: http://hgdp.uchicago.edu/) ( Supplementary Figure 5 ). 35 The results of this study suggest that pharmacological augmentation of HO-1 may represent a strategy for the treatment of diseases such as HIV, in which unchecked immune activation results in deleterious clinical outcomes. Given the increased burden of HIV disease in the African and the African-American subjects, such a strategy might prove to be particularly useful in these populations. Our study demonstrates that there are population-specific genetic variations of a GT n dinucleotide polymorphism involved in the control of HO-1 gene expression in immune cells that have an important role in HIV disease outcome. A recent clinical study reported that the synthetic metalloporphyrin Hematin (Fe 2 þ protoporphyrin IX) (Panhematin, Lundbeck Inc., Deerfield, IL, USA) can induce a 15-fold increase in HO-1 activity. 36 Further investigation of the HO-1 GT n microsatellite genetic locus may help us better understand the clinical pharmacogenetics of this type of intervention.
In summary, our data show that the HO-1 GT n microsatellite promoter polymorphism predicts expression of HO-1 in primary immune cells that have an important role in host interactions with HIV. We show that that greater additive GT n repeats correlate with higher levels of the inflammatory sCD14 biomarker in the African-Americans on HAART and of the mean viral load in subjects off-therapy. Finally, we show that the genetically determined level of HO-1 expression in monocytes correlates with the extent of LPS-induced loss of cell-surface CD14 expression within the healthy donors. This study highlights the potential role of the HO-1 GT n genetic locus as a predictive biomarker for disease outcome in the HIV-infected subjects on and off antiretroviral therapy.
MATERIALS AND METHODS
Human subjects
Peripheral blood samples were collected from HIV-infected anduninfected adults after written informed consent was obtained under protocols approved by the University of California at San Francisco Committee on Human Research (San Francisco, CA, USA). Healthy adults (n ¼ 22) were recruited from the San Francisco Bay Area (Table 1) . HIVpositive subjects were recruited from the San Francisco Bay Area into the UCSF-based Study of the Consequences of the Protease Inhibitor Era Cohort, a clinic-based cohort of 41500 adults with chronic HIV infection (Tables 2 and 3 ). Participants undergo clinical laboratory monitoring and have their biological specimens banked. HIV controllers are defined as HIVinfected subjects that are off antiretroviral therapy for at least the latest 12-month period for which a follow-up is available, with at least three plasma HIV RNA levels taken during this time below 1000 copies per ml. HIV viral non-controllers are defined as individuals with HIV RNA levels over 10 000 copies RNA per ml (by bDNA, Chiron Diagnostics, Emeryville, CA, USA) or 20 000 copies RNA per ml (by Abbott RealTime HIV-1 PCR, Abbott Park, IL, USA) at some point in the past, regardless if during a period of treatment or no treatment.
Measurement of plasma CD14 in HAART-suppressed subjects and mean viral loads in HIV-infected patients off-therapy
For sCD14 measurement in HAART-suppressed subjects (Table 3a) , a commercially available enzyme-linked immunosorbent assay was used according to the manufacturer's protocol (R&D Systems, Minneapolis, MN, USA). The mean viral loads measured in HIV-infected patients (Table 3b) were defined as the mean of all viral load determinations known to have been measured in the absence of therapy. All experiments were performed in a blinded manner without prior knowledge of an individual's genotype. 
Cell preparation and antibody labeling
All cells were stained with a live/dead marker Amine-Aqua/Am-Cyan Live/ Dead (Invitrogen, Carlsbad, CA, USA) to exclude dead cells from analysis.
The following fluorophore-conjugated monoclonal antibodies were used to detect cell surface markers: CD3-APC-Cy7 (SP34-2, BD Biosciences, Franklin Lakes, NJ, USA), CD14-Qdot605 (Q10013, Invitrogen) and CD16-APC (3G8, Caltag-Invitrogen, Burlingame, CA, USA). The following antibodies were used for the detection of intracellular antigens: HO-1 rabbit polyclonal (ab13243, unconjugated, Abcam, Cambridge, MA, USA) and a secondary goat antirabbit IgG conjugate (554020, FITC, BD Biosciences). For flow cytometry analysis, cells were washed in staining buffer (phosphatebuffered saline with 2% fetal bovine serum and 2 mM ethylenediamine tetra-acetic acid---EDTA (Sigma Aldrich) and then incubated for 30 min at 4 1C in the presence of directly conjugated fluorescent monoclonal antibodies. All the cells were stained with a live/dead marker (Amine-Aqua/Am-Cyan Live/Dead; Invitrogen), so that dead cells could be excluded from the analysis. The cells were washed in staining buffer, and then fixed and permeabilized in BD Cytofix/Cytoperm (BD Biosciences) according to the manufacturer's protocol for intracellular staining. The cells were incubated for 1 h at 4 1C in the presence of a rabbit polyclonal antibody specific for HO-1 (ab13243, unconjugated, Abcam) and a secondary goat antirabbit IgG conjugate (554020, FITC, BD Biosciences). The cells were washed in staining buffer and then fixed in 1% paraformaldehyde. Data were acquired with an LSR-II flow cytometer (BD Biosciences) and analyzed with FlowJo software (Treestar, Ashland, OR, USA). USA) and for the rs3761439 SNP probe was 5 0 -CATAGGGAGACCC[T/C] GTCT-3 0 (Custom assay, Applied Biosystems). Samples were run on the StepOnePlus Real-Time PCR system, and the results were analyzed using
DNA isolation and genotyping
Step One v2.0 (Applied Biosystems).
Quantitative PCR
For quantitative PCR analysis, cells were harvested and RNA was isolated using TRIzol Reagent (Invitrogen). Total cellular RNA (0.2 mg) was used for complementary DNA synthesis with Oligo-dT primers and reverse transcriptase from Omniscript (Qiagen). Relative expression levels of HO-1 mRNA were measured by quantitative RT-PCR using validated Taqman Gene Expression assay mixes for HO-1 (Assay ID: Hs00157965_m1, Applied Biosystems) and the reference gene, human hypoxanthine -guanine phosphoribosyl transferase (HPRT) (Assay ID: Hs99999909_m1, Applied Biosystems), according to the manufacturer's protocol. The StepOnePlus Real-Time PCR system (Applied Biosystems) was used for amplification and detection, and the efficiency-corrected calculation (2 ÀDCT ) of the threshold cycle C(t) was used to measure the HO-1 gene expression relative to the HPRT gene.
Transient transfection assay for Dual-glo gene expression assay
Transient co-transfection with the HO-1-luciferase fusion plasmid and the pRL-ef1alpha plasmid (Promega, Madison, WI, USA) was performed using the calcium phosphate method. For transfection, HEK293T cells were split 24 h before transfection and seeded in Dulbecco's Modified Eagle Medium (Gibco/Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Gemini Bio-Products, Woodland, CA, USA), 1% penicillin/ streptomycin (Mediatech), and 2 mM L-glutamine (Mediatech). The 10 Â co-transfection mix was made up with 1 mg of HMOX1-pGL4.20 and 0.1 mg of pRL-ef1alpha plasmid DNA in 200 mM CaCl 2 in Hepes buffered saline and added dropwise to the wells. Cells were harvested at 48 h, and the transfection efficiency and cell viability was analyzed by flow cytometric analysis of %GFP þ cells (mean 80% efficiency) Luciferase activity was analyzed using the Dual-Glo luciferase reporter assay system (Promega). Renilla luciferase activity in the lysates was used to normalize the activity of HMOX1 promoter-driven firefly luciferase activity on a Spectramax M2 luminometer (Molecular Devices, Sunnyvale, CA, USA).
Statistical and genetic analyses
Linkage disequilibrium analysis of the additive GT n repeats and the SNPs --1195A/G (rs3761439) and --413A/T (rs2071746) was carried out using the 'pwld' function (http://www-gene.cimr.cam.ac.uk/clayton). HO-1 GT n repeat differences between the African-Americans and the Caucasians (Figure 1b ), HO-1 relative qPCR levels before and after each stimulation condition using paired Student's t-test analysis (Figures 2a and b) , and HO-1 gMFI levels in CD14 hi monocytes before and after each stimulation condition using paired Student's t-test analysis (Figure 5b ) were all performed using GraphPad Prism v5.0d (Graphpad Software, La Jolla, CA, USA). We performed multiple linear regression of healthy donor HO-1 additive GT n repeats and the HO-1 relative qPCR levels upon different stimulation conditions (Figure 2c ) of HIV-infected subject additive GT n repeats and the HO-1 relative qPCR levels (Figures 3a and b) , for additive GT n repeats compared with mean viral load and post-HAART sCD14, and for comparing the normalized delta CD14 gMFI with normalized delta HO-1 gMFI in CD14 hi monocytes (Figure 5c ). For all correlation analyses, the Pearson r correlation and its P-values are reported using GraphPad Prism v5.0d (Graphpad Software). For all multiple regression analyses, the regression coefficient b was calculated and adjusted for ethnicity, age and gender when noted. All regression analyses were undertaken using STATA v11.2 (StataCorp LP, College Station, TX, USA).
